LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

MRK

119.64

-2.33%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

MRK

119.64

-2.33%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

MRK

119.64

-2.33%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

MRK

119.64

-2.33%↓

LLY

1,066.57

-0.02%↓

JNJ

230.23

-1.85%↓

ABBV

212.63

-1.61%↓

UNH

377.52

-2.74%↓

MRK

119.64

-2.33%↓

Home・Lista de Ações・CytoSorbents Corp

CytoSorbents Corp

Fechado

SetorSaúde

0.45 2.27

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.42

Máximo

0.46

Indicadores-chave
By Trading Economics
Rendimento	368K -5.1M
Vendas	-370K 8.9M
EPS	-0.08
Margem de lucro	-57.863
Funcionários	129
EBITDA	648K -3M

Recomendações
By TipRanks
Recomendações	Neutro
Previsão para 12 meses	+63.04% upside

Dividendos
By Dow Jones
Próximos Ganhos	6 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-11M 29M
Abertura anterior	-1.82
Fecho anterior	0.45

Sentimento de Notícias

By Acuity

46%

54%

140 / 344 Ranking em Healthcare

CytoSorbents Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

26 de mai. de 2026, 16:52 UTC

Notícias Principais

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

26 de mai. de 2026, 23:57 UTC

Ganhos

Sociedad Quimica 1Q Rev $1.76B >SQM

26 de mai. de 2026, 23:57 UTC

Ganhos

Sociedad Quimica 1Q EPS $1.28 >SQM

26 de mai. de 2026, 23:48 UTC

Conversa de Mercado

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

26 de mai. de 2026, 21:54 UTC

Ganhos

Webco Industries 3Q EPS $11.61 >WEBC

26 de mai. de 2026, 21:54 UTC

Ganhos

Webco Industries 3Q Sales $179.6M >WEBC

26 de mai. de 2026, 21:48 UTC

Conversa de Mercado

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

26 de mai. de 2026, 21:00 UTC

Conversa de Mercado

ESG Roundup: Market Talk

26 de mai. de 2026, 20:58 UTC

Aquisições, Fusões, Aquisições de Empresas

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

26 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

26 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

26 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

26 de mai. de 2026, 19:22 UTC

Conversa de Mercado

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

26 de mai. de 2026, 19:17 UTC

Conversa de Mercado

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

26 de mai. de 2026, 18:56 UTC

Conversa de Mercado

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

26 de mai. de 2026, 18:03 UTC

Conversa de Mercado

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

26 de mai. de 2026, 17:42 UTC

Conversa de Mercado

Grains Await Fresh Trading Catalyst -- Market Talk

26 de mai. de 2026, 17:33 UTC

Conversa de Mercado

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

26 de mai. de 2026, 17:21 UTC

Conversa de Mercado

Canada Faces a Labor Market Squeeze -- Market Talk

26 de mai. de 2026, 16:52 UTC

Conversa de Mercado

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

26 de mai. de 2026, 16:43 UTC

Conversa de Mercado

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

26 de mai. de 2026, 16:24 UTC

Conversa de Mercado

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

26 de mai. de 2026, 16:21 UTC

Conversa de Mercado

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

26 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

26 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Energy & Utilities Roundup: Market Talk

26 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

26 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Auto & Transport Roundup: Market Talk

26 de mai. de 2026, 16:16 UTC

Conversa de Mercado

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

26 de mai. de 2026, 16:01 UTC

Conversa de Mercado

Bitcoin Lower as Stress Builds for Holders -- Market Talk

26 de mai. de 2026, 15:21 UTC

Conversa de Mercado

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Comparação entre Pares

Variação de preço

CytoSorbents Corp Previsão

Preço-alvo

By TipRanks

63.04% parte superior

Previsão para 12 meses

Média 0.75 USD 63.04%

Máximo 0.75 USD

Mínimo 0.75 USD

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para CytoSorbents Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

1 ratings

Comprar

Manter

Vender

Com base em 1 analistas que deram avaliações de ações para CytoSorbents Corp - Dist nos últimos 3 meses.

Sentimento

By Acuity

140 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.